References
- Innes EA. A brief history and overview of Toxoplasma gondii. Zoonoses Public Health 2010;57:1–7.
- Schwartzman JD, Maguire JH. Toxoplasmosis in tropical infectious diseases: principles, pathogens and practice. 3rd ed. Edinburgh, U.K.: W. B. Saunders; 2011: 722–28.
- Hill DE, Chirukandoth S, Dubey JP. Biology and epidemiology of Toxoplasma gondii in man and animals. Anim Health Res Rev 2005;6:41–61.
- Walker DM, Oghumu S, Gupta G, et al. Mechanisms of cellular invasion by intracellular parasites. Cell Mol Life Sci 2014;71:1245–63.
- Pittman KJ, Knoll LJ. Long-term relationships: the complicated interplay between the host and the developmental stages of Toxoplasma gondii during acute and chronic infections. Microbiol Mol Biol Rev 2015;79:387–401.
- Kongsaengdao S, Samintarapanya K, Oranratnachai K, et al. Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients. J Int Assoc Physicians AIDS Care 2008;7:11–16.
- Yolken RH, Bachmann S, Rouslanova I, et al. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. J Clin Infect Dis 2001;32:842–4.
- Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res 2003;62:237–44.
- Kravetz J. Congenital toxoplasmosis. BMJ Clin Evid 2013;8:906.
- Rodriguez JB, Szajnman SH. New antibacterials for the treatment of toxoplasmosis; a patent review. Expert Opin Ther Pat 2012;22:311–33.
- Liñares GE, Ravaschino EL, Rodriguez JB. Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Curr Med Chem 2006;13:335–60.
- Wei H-X, Wei S-S, Lindsay DS, Peng H-J. A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans. PLoS One 2015;10:e0138204.
- Meneceur P, Bouldouyre M, Aubert D, et al. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob Agents Chemother 2008;52:1269–77.
- Doggett JS, Nilsen A, Forquer I, et al. Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc Natl Acad Sci USA 2012;109:15936–41.
- Mui EJ, Schiehser GA, Milhous WK, et al. Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis 2008;2:e190
- Dzitko K, Paneth A, Plech T, et al. 1,4-Disubstituted thiosemicarbazide derivatives are potent inhibitors of Toxoplasma gondii proliferation. Molecules 2014;19:9926–43.
- Krivogorsky B, Grundt P, Yolken R, Jones-Brando L. Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs. Antimicrob Agents Chemother 2008;52:4466–9.
- Chimenti F, Bizzarri B, Bolasco A, et al. Synthesis and evaluation of 4-acyl-2-thiazolylhydrazone derivatives for anti-Toxoplasma efficacy in vitro. J Med Chem 2009;52:4574–7.
- D’Ascenzio M, Bizzarri B, De Monte C, et al. Design, synthesis and biological characterization of thiazolidin-4-one derivatives as promising inhibitors of Toxoplasma gondii. Eur J Med Chem 2014;86:17–30.
- (a) De Monte C, Carradori S, Bizzarri B, et al. Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives. Eur J Med Chem 2016;107:82–96. (b) Secci D, Carradori S, Bizzarri B, et al. Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties. Eur J Med Chem 2016;117:144–56.
- Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 1998;11:267–99.